LivaNova (LIVN) Cash from Financing Activities (2015 - 2026)
LivaNova's (LIVN) quarterly Cash from Financing Activities came in at -$56.4 million in Q2 2026, up 72.99% year-over-year from -$32.6 million in Q2 2025, and up 40.11% quarter-over-quarter from -$94.2 million in Q1 2026.
Analysis
LivaNova (LIVN) Cash from Financing Activities (2015 - 2026) Analysis & Trends
LivaNova has disclosed Cash from Financing Activities across 12 years of filings, most recently posting -$56.4 million for Q2 2026.
- In Q2 2026, Cash from Financing Activities rose 72.99% year-over-year to -$56.4 million; the TTM figure through Jun 2026 stood at -$223.0 million (down 1.28% YoY), while the FY2025 annual figure was -$285.7 million, down 1639.86% from the prior year.
- Cash from Financing Activities came in at -$56.4 million for Q2 2026 at LivaNova, up from -$94.2 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $214.9 million in Q1 2022 to a low of -$209.0 million in Q2 2025.
- Average Cash from Financing Activities over 5 years is -$6.5 million, with a median of -$4.7 million recorded in 2023.
- Year-over-year, Cash from Financing Activities soared 2680.18% in 2022 and sank 2031.76% in 2026.
- Over 5 years, Cash from Financing Activities stood at -$1.7 million in 2022, then plunged by 202.84% to -$5.0 million in 2023, then surged by 31.37% to -$3.4 million in 2024, then tumbled by 1725.9% to -$62.9 million in 2025, then rose by 10.23% to -$56.4 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$56.4 million in Q2 2026, -$94.2 million in Q1 2026, and -$62.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | -287.90 Mn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | -343.00 Mn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | -95.00 Mn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | -410.00 Mn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | -300,000.00 |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | -510.00 Mn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | -607.30 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | -213.50 Mn |
| 10 | LivaNova | 4.34 Bn | 3.82 Bn | 273.67 Mn | -56.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -56.45 Mn |
| Mar 31, 2026 | -94.25 Mn |
| Dec 31, 2025 | -62.88 Mn |
| Sep 30, 2025 | -9.37 Mn |
| Jun 30, 2025 | -208.98 Mn |
| Mar 31, 2025 | -4.42 Mn |
| Dec 31, 2024 | -3.44 Mn |
| Sep 30, 2024 | -3.28 Mn |
| Jun 30, 2024 | -11.87 Mn |
| Mar 31, 2024 | 37.15 Mn |
| Dec 31, 2023 | -5.02 Mn |
| Sep 30, 2023 | -4.28 Mn |
| Jun 30, 2023 | 36.01 Mn |
| Mar 31, 2023 | -5.24 Mn |
| Dec 31, 2022 | -1.66 Mn |
| Sep 30, 2022 | 73.23 Mn |
| Jun 30, 2022 | -6.32 Mn |
| Mar 31, 2022 | 214.88 Mn |
| Dec 31, 2021 | -3.30 Mn |
| Sep 30, 2021 | -164.10 Mn |